United States——

Multiply Labs

San Francisco maker of robotic systems that automate GMP manufacturing of cell and gene therapies and other biologics.

About

Multiply Labs, founded in 2016 and a Y Combinator alumnus, builds robotic systems that automate manual steps in manufacturing cell and gene therapies and is expanding to antibodies, viral vectors and mRNA. Its systems are owned and operated by drug makers rather than run as an outsourced service. It raised a $75 million Series B led by Patrick Soon-Shiong in October 2026, taking total funding above $100 million, according to the company.

Key stats

Latest funding: $75M Series B
Total funding: $75M
Latest valuation: —
Founded: 2016
Country: United States

Latest roundsAll rounds

Oct 6, 2026Series B$75M
Led by Patrick Soon-ShiongAstraZeneca Lingotto Teradyne Strange Ventures Casdin Capital Lux Capital Fifty Years Ora Global Founders Fund

Recent newsAll news

Oct 7, 2026FundingMecka's $60 million Series B: Sequoia, NVIDIA and Samsung back a robot-data supplier claiming a $100 million revenue run rate
Oct 7, 2026FundingMultiply Labs raises $75 million led by Patrick Soon-Shiong to scale robots that make cell and gene therapies